MTOR and hepatocellular carcinoma: Considering that mTOR sits at the intersection of a number of signaling pathways and the diverse clinical and molecular heterogeneity of HCC, it is highly plausible that a myriad of feedback mechanisms, for example the sustained activation of AKT, can over-ride the specificity of a mTOR inhibitor.